- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Drug Pipelines
- March 2024
- 180 Pages
Global
From €2417EUR$2,500USD£2,076GBP
- Report
- November 2022
- 154 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Drug Pipelines
- November 2020
- 95 Pages
Global
From €3384EUR$3,500USD£2,906GBP
- Report
- October 2023
- 140 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Drug Pipelines
- August 2018
- 52 Pages
Global
From €3384EUR$3,500USD£2,906GBP
- Book
- July 2018
- 360 Pages
- Book
- March 2010
- 720 Pages
The Cancer CDK Inhibitor market is a subset of the Oncology Drugs market, focusing on drugs that inhibit the activity of cyclin-dependent kinases (CDKs). CDKs are proteins that regulate the cell cycle, and their inhibition can lead to cell death in cancer cells. CDK inhibitors are used to treat a variety of cancers, including breast, lung, and colorectal cancer. These drugs are typically administered orally or intravenously, and can be used in combination with other cancer treatments.
The Cancer CDK Inhibitor market is highly competitive, with many companies developing and marketing these drugs. Some of the major players in the market include Novartis, Pfizer, Merck, AstraZeneca, and Eli Lilly. Other companies, such as Gilead Sciences, Bristol-Myers Squibb, and Celgene, are also active in the market. Show Less Read more
